Comparing the current results to its competitors, Regencell Bioscience Holdings Limited reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Regencell Bioscience Holdings Limited's competitors' average revenue growth of 17.36 %, achieved in the same quarter.
Regencell Bioscience Holdings Limited, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 83.87 %
Regencell Bioscience Holdings Limited's Comment on Competition and Industry Peers
The company operates in the traditional Chinese medicine (TCM) market for ADHD and ASD in Hong Kong, a sector characterized by fragmentation and the absence of major TCM competitors. Its focus is on TCM products, distinguishing it from global pharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Fusion Autism Center, Pfizer Inc., and Otsuka Holdings Co. Limited, which primarily offer prescription or over-the-counter drugs. The company intends to commercialize its TCM formula in Hong Kong following the acquisition of necessary regulatory approvals and plans to consider international expansion only after establishing its presence in the Hong Kong market.
Publicly Traded Peers of Regencell Bioscience Holdings Limited
Astrazeneca Plc Share Performance
-7.70%
This Quarter
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Regencell Bioscience Holdings Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Regencell Bioscience Holdings Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
